Chitkala Kalidas, PhD, is the Global Head of Oncology Regulatory Affairs and Oncology Sustainability at Bayer. Dr. Kalidas and her team of global regulatory affairs professionals are responsible for developing global regulatory strategies for programs in all stages of drug development and for the registration of drugs as well as in vitro diagnostics. Dr. Kalidas also leads the Oncology Sustainability Initiative at Bayer. This initiative, which is focused on Global Health Equity in underserved communities around the globe, reflects Bayer’s commitment to remedy disparities in access to quality cancer care and bring to life Bayer’s vision of Health for All.
Dr. Kalidas is active in the area of multi-stakeholder collaboration to enhance access to cancer clinical trials as well as regulatory science and innovation to expedite availability of innovative cancer therapies to patients. She represents Bayer at several multi-stakeholder forums to accelerate cancer drug development and improve cancer care equity in underserved communities.
Dr. Kalidas has over 20 years of experience in drug development. Prior to joining Bayer, Dr. Kalidas was at Merck & Co. Inc. where she worked on drug development programs across multiple therapeutic areas and geographic regions. Prior to joining the pharmaceutical industry, she was a Management Consultant at the Boston Consulting Group. Dr. Kalidas has a PhD in Microbiology from Cornell University.
